entertainment -WSS

entertainment

author：hotspot 2025-09-06 02:15:19 - browse：98

The corporate offices of Massachusetts General Brigham hospitals in Assembly Square in Somerville. Lane Turner/Globe Staff

The severing of ties between two of Boston’s biggest health care giants has placed one of the nation’s largest health care systems in the position of figuring out how, exactly, to fill a new hole in its oncology services, at a time when cancer care is changing rapidly.

Earlier this month, Dana-Farber Cancer Institute surprised the medical community and even its partner, Brigham and Women’s Hospital, when it announced that it would end their nearly 30-year collaboration. The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians.

Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives. The two parties had been in discussions about extending their contract for months when the split was announced. “The decision was made by the Farber. It was announced. Now, we just have to plan forward,” she said. Klibanski shared her views on the split at a meeting with Boston Globe opinion editors on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Bird flu in milk supply is likely coming from asymptomatic cows

WSS

Cell therapy fails to slow type 1 diabetes, but safety is established

Bird flu outbreak in cows is latest avian flu curveball

Parkinson’s finding may lead to tests and, someday, treatments

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Exact Sciences stock tumbles despite strong cancer detection sales

H5N1 bird flu virus started spreading in cows in Texas in December

hotspot

entertainment

explore

At least 13 dead in Texas as scorching temps continue

Element Biosciences CEO lays out genome sequencing strategy

Moonlake's readout produced a cash windfall. Risks remain

NIH director takes cautious approach to Biden drug pricing priority

New air purifier tech could be key to improving indoor air quality

Biotech venture capitalists face new demands from investors

Sports medicine is finally prioritizing gender equality

Biotech venture capitalists face new demands from investors

Peter Hotez and the public health issue of online harassment

Research misconduct: Proposed new rules face resistance

hotspot

Diversity in clinical trials starts with building trust, experts say

How digital therapeutics firms are pivoting after Pear's bankruptcy

Dewpoint Therapeutics lays off staff after losing partnerships

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

MultiPlan and major insurers sued for alleged medical price

Eli Lilly, Pfizer, and others want in on the online prescription market

explore

focus

hotspot

focus